News Releases
View printer-friendly version < < back
Net earnings and diluted earnings per share for the third quarter of 2018 were
"We are pleased with our strong third-quarter performance, which reflects continued above-market growth in our Pharmaceutical business, accelerating sales momentum in our Consumer business and consistent progress in our Medical Devices business," said
The Company issued sales guidance for the full-year 2018 in a range of
Segment Sales Performance
Worldwide Consumer sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products including MOTRIN and TYLENOL analgesics, ZYRTEC upper respiratory and IMODIUM digestive health products; beauty products including NEUTROGENA, OGX and DR. CI LABO; as well as domestic sales of JOHNSON's baby care products.
During the quarter, the acquisition of Zarbee's, Inc., a leader in naturally-based healthcare products, was completed.
Worldwide Pharmaceutical sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, TREMFYA (guselkumab), for the treatment of adults living with moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, SIMPONI/SIMPONI ARIA (golimumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, and UPTRAVI (selexipag), an oral prostacyclin receptor agonist used to treat pulmonary arterial hypertension and reduce hospitalization.
During the quarter, the
A New Drug Application was submitted to the FDA for esketamine nasal spray, a rapidly acting antidepressant for treatment-resistant depression in adults and erdafitinib, a once-daily, oral pan-fibroblast growth factor receptor (FGFR) inhibitor for the treatment of locally advanced or metastatic urothelial cancer. A supplemental New Drug Application was submitted to the FDA seeking to broaden the use of IMBRUVICA (ibrutinib) in chronic lymphocytic leukemia or small lymphocytic lymphoma to include combination use with a non-chemotherapy agent, obinutuzumab, in the frontline setting. A Type II Variation was submitted to the
Subsequent to the quarter, the FDA approved an additional indication for XARELTO (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction and stroke, in people with chronic coronary or peripheral artery disease. Additionally, a Marketing Authorization Application was submitted to the EMA for esketamine nasal spray, a rapidly acting antidepressant for treatment-resistant depression in adults. The Company also entered into an exclusive worldwide license agreement with Arrowhead Pharmaceuticals, Inc. to develop and commercialize a new treatment for chronic Hepatitis B viral infection.
Worldwide Medical Devices sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by the growth of electrophysiology products in the Interventional Solutions business; ACUVUE contact lenses in the Vision business; endocutters and biosurgicals in the Advanced Surgery business; and wound closure products in the General Surgery business, partially offset by declines in the Diabetes Care business.
During the quarter, the Company received European CE mark approval for its BRAVO Flow Diverter for use in the treatment of patients suffering from intracranial aneurysms. In addition, the acquisition of
Subsequent to the quarter, the Company announced the completion of the divestiture of its
About
At
* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
THIRD QUARTER |
NINE MONTHS |
|||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2018 |
2017 |
Total |
Operations |
Currency |
2018 |
2017 |
Total |
Operations |
Currency |
||||||||||
Sales to customers by |
|||||||||||||||||||
segment of business |
|||||||||||||||||||
Consumer |
|||||||||||||||||||
|
$ 1,370 |
1,285 |
6.6 |
% |
6.6 |
- |
$ 4,282 |
4,186 |
2.3 |
% |
2.3 |
- |
|||||||
International |
2,045 |
2,071 |
(1.3) |
3.7 |
(5.0) |
6,035 |
5,876 |
2.7 |
1.6 |
1.1 |
|||||||||
3,415 |
3,356 |
1.8 |
4.9 |
(3.1) |
10,317 |
10,062 |
2.5 |
1.9 |
0.6 |
||||||||||
Pharmaceutical |
|||||||||||||||||||
|
6,097 |
5,816 |
4.8 |
4.8 |
- |
17,350 |
15,698 |
10.5 |
10.5 |
- |
|||||||||
International |
4,249 |
3,879 |
9.5 |
13.2 |
(3.7) |
13,194 |
10,877 |
21.3 |
17.5 |
3.8 |
|||||||||
10,346 |
9,695 |
6.7 |
8.2 |
(1.5) |
30,544 |
26,575 |
14.9 |
13.4 |
1.5 |
||||||||||
Medical Devices |
|||||||||||||||||||
|
3,197 |
3,189 |
0.3 |
0.3 |
- |
9,623 |
9,510 |
1.2 |
1.2 |
- |
|||||||||
International |
3,390 |
3,410 |
(0.6) |
3.0 |
(3.6) |
10,703 |
10,108 |
5.9 |
3.2 |
2.7 |
|||||||||
6,587 |
6,599 |
(0.2) |
1.7 |
(1.9) |
20,326 |
19,618 |
3.6 |
2.2 |
1.4 |
||||||||||
|
10,664 |
10,290 |
3.6 |
3.6 |
- |
31,255 |
29,394 |
6.3 |
6.3 |
- |
|||||||||
International |
9,684 |
9,360 |
3.5 |
7.5 |
(4.0) |
29,932 |
26,861 |
11.4 |
8.6 |
2.8 |
|||||||||
Worldwide |
|
19,650 |
3.6 |
% |
5.5 |
(1.9) |
|
56,255 |
8.8 |
% |
7.5 |
1.3 |
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
THIRD QUARTER |
NINE MONTHS |
|||||||||||||||||
Percent Change |
Percent Change |
||||||||||||||||||
2018 |
2017 |
Total |
Operations |
Currency |
2018 |
2017 |
Total |
Operations |
Currency |
||||||||||
Sales to customers by |
|||||||||||||||||||
geographic area |
|||||||||||||||||||
|
|
10,290 |
3.6 |
% |
3.6 |
- |
|
29,394 |
6.3 |
% |
6.3 |
- |
|||||||
|
4,416 |
4,308 |
2.5 |
5.1 |
(2.6) |
14,023 |
12,398 |
13.1 |
7.1 |
6.0 |
|||||||||
Western Hemisphere excluding |
1,550 |
1,569 |
(1.2) |
11.2 |
(12.4) |
4,657 |
4,522 |
3.0 |
8.4 |
(5.4) |
|||||||||
|
3,718 |
3,483 |
6.7 |
8.6 |
(1.9) |
11,252 |
9,941 |
13.2 |
10.8 |
2.4 |
|||||||||
International |
9,684 |
9,360 |
3.5 |
7.5 |
(4.0) |
29,932 |
26,861 |
11.4 |
8.6 |
2.8 |
|||||||||
Worldwide |
|
19,650 |
3.6 |
% |
5.5 |
(1.9) |
|
56,255 |
8.8 |
% |
7.5 |
1.3 |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
THIRD QUARTER |
||||||||
2018 |
2017* |
Percent |
|||||||
Percent |
Percent |
Increase |
|||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
|||||
Sales to customers |
|
100.0 |
|
100.0 |
3.6 |
||||
Cost of products sold |
6,589 |
32.4 |
6,925 |
35.2 |
(4.9) |
||||
Gross Profit |
13,759 |
67.6 |
12,725 |
64.8 |
8.1 |
||||
Selling, marketing and administrative expenses |
5,543 |
27.3 |
5,423 |
27.6 |
2.2 |
||||
Research and development expense |
2,508 |
12.3 |
2,585 |
13.2 |
(3.0) |
||||
In-process research and development |
1,126 |
5.6 |
- |
- |
|||||
Interest (income) expense, net |
68 |
0.3 |
155 |
0.8 |
|||||
Other (income) expense, net |
3 |
0.0 |
(297) |
(1.5) |
|||||
Restructuring |
88 |
0.4 |
69 |
0.3 |
|||||
Earnings before provision for taxes on income |
4,423 |
21.7 |
4,790 |
24.4 |
(7.7) |
||||
Provision for taxes on income |
489 |
2.4 |
1,026 |
5.2 |
(52.3) |
||||
Net earnings |
$ 3,934 |
19.3 |
$ 3,764 |
19.2 |
4.5 |
||||
Net earnings per share (Diluted) |
$ 1.44 |
$ 1.37 |
5.1 |
||||||
Average shares outstanding (Diluted) |
2,727.6 |
2,737.7 |
|||||||
Effective tax rate |
11.1 |
% |
21.4 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
$ 6,780 |
33.3 |
$ 6,573 |
33.5 |
3.1 |
||||
Net earnings |
$ 5,590 |
27.5 |
$ 5,208 |
26.5 |
7.3 |
||||
Net earnings per share (Diluted) |
$ 2.05 |
$ 1.90 |
7.9 |
||||||
Effective tax rate |
17.6 |
% |
20.8 |
% |
|||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
|||||||||
*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07 |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
NINE MONTHS |
||||||||
2018 |
2017* |
Percent |
|||||||
Percent |
Percent |
Increase |
|||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) |
|||||
Sales to customers |
|
100.0 |
|
100.0 |
8.8 |
||||
Cost of products sold |
20,130 |
32.9 |
18,180 |
32.3 |
10.7 |
||||
Gross Profit |
41,057 |
67.1 |
38,075 |
67.7 |
7.8 |
||||
Selling, marketing and administrative expenses |
16,549 |
27.1 |
15,475 |
27.5 |
6.9 |
||||
Research and development expense |
7,551 |
12.3 |
6,951 |
12.4 |
8.6 |
||||
In-process research and development |
1,126 |
1.8 |
- |
- |
|||||
Interest (income) expense, net |
340 |
0.6 |
360 |
0.6 |
|||||
Other (income) expense, net |
427 |
0.7 |
11 |
0.0 |
|||||
Restructuring |
187 |
0.3 |
165 |
0.3 |
|||||
Earnings before provision for taxes on income |
14,877 |
24.3 |
15,113 |
26.9 |
(1.6) |
||||
Provision for taxes on income |
2,622 |
4.3 |
3,100 |
5.5 |
(15.4) |
||||
Net earnings |
|
20.0 |
|
21.4 |
2.0 |
||||
Net earnings per share (Diluted) |
$ 4.49 |
$ 4.37 |
2.7 |
||||||
Average shares outstanding (Diluted) |
2,729.6 |
2,746.4 |
|||||||
Effective tax rate |
17.6 |
% |
20.5 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
|
33.8 |
|
33.7 |
8.9 |
||||
Net earnings |
|
27.7 |
|
27.1 |
11.0 |
||||
Net earnings per share (Diluted) |
$ 6.21 |
$ 5.56 |
11.7 |
||||||
Effective tax rate |
18.0 |
% |
19.5 |
% |
|||||
(1)See Reconciliation of Non-GAAP Financial Measures. |
|||||||||
*2017 Statement of Earnings line items have been restated to reflect impact of ASU 2017-07 |
|
||||||||||||||
Reconciliation of Non-GAAP Financial Measures |
||||||||||||||
Third Quarter |
% Incr. / |
Nine Months YTD |
% Incr. / |
|||||||||||
(Dollars in Millions Except Per Share Data) |
2018 |
2017 |
(Decr.) |
2018 |
2017 |
(Decr.) |
||||||||
Earnings before provision for taxes on income - as reported |
$ 4,423 |
4,790 |
(7.7) |
% |
$ 14,877 |
15,113 |
(1.6) |
% |
||||||
Intangible asset amortization expense |
1,085 |
1,077 |
3,284 |
1,886 |
||||||||||
In-process research and development |
1,126 |
- |
1,126 |
- |
||||||||||
Litigation expense, net |
- |
118 |
703 |
611 |
||||||||||
Restructuring/Other (1) |
190 |
187 |
473 |
476 |
||||||||||
|
40 |
367 |
200 |
580 |
||||||||||
Contingent liability reversal |
(184) |
- |
(184) |
- |
||||||||||
AMO acquisition related cost |
36 |
36 |
82 |
115 |
||||||||||
Diabetes asset impairment |
- |
(2) |
4 |
180 |
||||||||||
Unrealized loss/(gain) on securities |
9 |
- |
(3) |
- |
||||||||||
Other |
55 |
- |
90 |
- |
||||||||||
Earnings before provision for taxes on income - as adjusted |
$ 6,780 |
6,573 |
3.1 |
% |
$ 20,652 |
18,961 |
8.9 |
% |
||||||
Net Earnings - as reported |
$ 3,934 |
3,764 |
4.5 |
% |
$ 12,255 |
12,013 |
2.0 |
% |
||||||
Intangible asset amortization expense |
968 |
933 |
2,931 |
1,555 |
||||||||||
In-process research and development |
859 |
- |
859 |
- |
||||||||||
Litigation expense, net |
- |
97 |
609 |
449 |
||||||||||
Restructuring/Other |
162 |
136 |
395 |
358 |
||||||||||
|
37 |
255 |
193 |
454 |
||||||||||
Contingent liability reversal |
(184) |
- |
(184) |
- |
||||||||||
AMO acquisition related cost |
29 |
28 |
68 |
314 |
||||||||||
Diabetes asset impairment |
- |
(5) |
3 |
120 |
||||||||||
Unrealized loss/(gain) on securities |
8 |
- |
(2) |
- |
||||||||||
Impact of tax legislation (2) |
(265) |
- |
(253) |
- |
||||||||||
Other |
42 |
- |
69 |
- |
||||||||||
Net Earnings - as adjusted |
$ 5,590 |
5,208 |
7.3 |
% |
$ 16,943 |
15,263 |
11.0 |
% |
||||||
Diluted Net Earnings per share - as reported |
$ 1.44 |
1.37 |
5.1 |
% |
$ 4.49 |
4.37 |
2.7 |
% |
||||||
Intangible asset amortization expense |
0.35 |
0.34 |
1.07 |
0.57 |
||||||||||
In-process research and development |
0.32 |
- |
0.32 |
- |
||||||||||
Litigation expense, net |
- |
0.04 |
0.22 |
0.16 |
||||||||||
Restructuring/Other |
0.06 |
0.05 |
0.15 |
0.14 |
||||||||||
|
0.02 |
0.09 |
0.07 |
0.16 |
||||||||||
Contingent liability reversal |
(0.07) |
- |
(0.07) |
- |
||||||||||
AMO acquisition related cost |
0.01 |
0.01 |
0.02 |
0.11 |
||||||||||
Diabetes asset impairment |
- |
- |
- |
0.05 |
||||||||||
Unrealized loss/(gain) on securities |
- |
- |
- |
- |
||||||||||
Impact of tax legislation |
(0.10) |
- |
(0.09) |
- |
||||||||||
Other |
0.02 |
- |
0.03 |
- |
||||||||||
Diluted Net Earnings per share - as adjusted |
$ 2.05 |
1.90 |
7.9 |
% |
$ 6.21 |
5.56 |
11.7 |
% |
||||||
Operational Diluted Net Earnings per share - as adjusted |
||||||||||||||
at 2016 foreign currency exchange rates |
1.85 |
5.57 |
||||||||||||
Impact of currency at 2017 foreign currency exchange rates |
0.03 |
0.05 |
(0.17) |
(0.01) |
||||||||||
Operational Diluted Net Earnings per share - as adjusted |
||||||||||||||
at 2017 foreign currency exchange rates |
$ 2.08 |
1.90 |
9.5 |
% |
$ 6.04 |
5.56 |
8.6 |
% |
||||||
(1)Includes |
||||||||||||||
and |
||||||||||||||
third quarter 2017. Includes |
||||||||||||||
(2)Includes foreign currency translation |
|
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures |
||||||||
THIRD QUARTER 2018 ACTUAL vs. 2017 ACTUAL |
||||||||
Segments |
||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total |
|||||
Operational % (1) |
||||||||
WW As Reported: |
4.9% |
8.2% |
1.7% |
5.5% |
||||
U.S. |
6.6% |
4.8% |
0.3% |
3.6% |
||||
International |
3.7% |
13.2% |
3.0% |
7.5% |
||||
Spine & Other |
||||||||
Codman Neuroscience |
1.0 |
0.4 |
||||||
U.S. |
0.6 |
0.2 |
||||||
International |
1.4 |
0.5 |
||||||
Wound Care / Other |
||||||||
Compeed |
0.8 |
0.1 |
||||||
U.S. |
0.0 |
0.0 |
||||||
International |
1.3 |
0.3 |
||||||
Beauty |
||||||||
Nizoral |
0.5 |
0.1 |
||||||
U.S. |
0.3 |
0.0 |
||||||
International |
0.7 |
0.1 |
||||||
All Other Acquisitions and Divestitures |
(0.1) |
0.0 |
0.2 |
0.0 |
||||
U.S. |
(0.5) |
0.0 |
0.3 |
0.1 |
||||
International |
0.2 |
0.0 |
0.0 |
0.1 |
||||
WW Ops excluding Acquisitions and Divestitures |
6.1% |
8.2% |
2.9% |
6.1% |
||||
U.S. |
6.4% |
4.8% |
1.2% |
3.9% |
||||
International |
5.9% |
13.2% |
4.4% |
8.5% |
||||
(1)Operational growth excludes the effect of translational currency |
|
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures |
||||||||
NINE MONTHS 2018 ACTUAL vs. 2017 ACTUAL |
||||||||
Segments |
||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total |
|||||
Operational % (1) |
||||||||
WW As Reported: |
1.9% |
13.4% |
2.2% |
7.5% |
||||
U.S. |
2.3% |
10.5% |
1.2% |
6.3% |
||||
International |
1.6% |
17.5% |
3.2% |
8.6% |
||||
Pulmonary Hypertension |
||||||||
|
(4.3) |
(2.0) |
||||||
U.S. |
(4.7) |
(2.5) |
||||||
International |
(3.8) |
(1.6) |
||||||
Cardiovascular / Metabolism / Other |
||||||||
|
(0.2) |
(0.1) |
||||||
U.S. |
(0.1) |
(0.1) |
||||||
International |
(0.3) |
(0.1) |
||||||
Spine & Other |
||||||||
Codman Neuroscience |
1.0 |
0.4 |
||||||
U.S. |
0.6 |
0.3 |
||||||
International |
1.4 |
0.6 |
||||||
Wound Care / Other |
||||||||
Compeed |
0.9 |
0.2 |
||||||
U.S. |
0.0 |
0.0 |
||||||
International |
1.5 |
0.3 |
||||||
Vision |
||||||||
Vision Surgical & Eye Health Business |
(1.0) |
(0.4) |
||||||
U.S. |
(0.9) |
(0.3) |
||||||
International |
(1.1) |
(0.4) |
||||||
Beauty |
||||||||
Nizoral |
0.2 |
0.0 |
||||||
U.S. |
0.1 |
0.0 |
||||||
International |
0.3 |
0.1 |
||||||
All Other Acquisitions and Divestitures |
0.0 |
0.0 |
0.1 |
0.0 |
||||
U.S. |
(0.1) |
0.0 |
0.0 |
0.0 |
||||
International |
0.2 |
0.0 |
0.2 |
0.1 |
||||
WW Ops excluding Acquisitions and Divestitures |
3.0% |
8.9% |
2.3% |
5.6% |
||||
U.S. |
2.3% |
5.7% |
0.9% |
3.7% |
||||
International |
3.6% |
13.4% |
3.7% |
7.6% |
||||
(1)Operational growth excludes the effect of translational currency |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||||||||||||
THIRD QUARTER |
NINE MONTHS |
|||||||||||||||||
% Change |
% Change |
|||||||||||||||||
2018 |
2017 |
Reported |
Operational (1) |
Currency |
2018 |
2017 |
Reported |
Operational (1) |
Currency |
|||||||||
CONSUMER SEGMENT (2) |
||||||||||||||||||
|
||||||||||||||||||
US |
$ 120 |
$ 100 |
20.0% |
20.0% |
- |
$ 306 |
$ 326 |
-6.1% |
-6.1% |
- |
||||||||
Intl |
352 |
377 |
-6.6% |
0.1% |
-6.7% |
1,079 |
1,100 |
-1.9% |
-0.5% |
-1.4% |
||||||||
WW |
472 |
477 |
-1.0% |
4.3% |
-5.3% |
1,385 |
1,426 |
-2.9% |
-1.8% |
-1.1% |
||||||||
BEAUTY |
||||||||||||||||||
US |
543 |
523 |
3.8% |
3.8% |
- |
1,791 |
1,739 |
3.0% |
3.0% |
- |
||||||||
Intl |
535 |
510 |
4.9% |
9.2% |
-4.3% |
1,480 |
1,351 |
9.5% |
7.7% |
1.8% |
||||||||
WW |
1,078 |
1,033 |
4.4% |
6.5% |
-2.1% |
3,271 |
3,090 |
5.9% |
5.1% |
0.8% |
||||||||
|
||||||||||||||||||
US |
158 |
154 |
2.6% |
2.6% |
- |
472 |
460 |
2.6% |
2.6% |
- |
||||||||
Intl |
226 |
228 |
-0.9% |
3.6% |
-4.5% |
684 |
678 |
0.9% |
-0.5% |
1.4% |
||||||||
WW |
384 |
382 |
0.5% |
3.2% |
-2.7% |
1,156 |
1,138 |
1.6% |
0.7% |
0.9% |
||||||||
OTC |
||||||||||||||||||
US |
440 |
401 |
9.7% |
9.7% |
- |
1,359 |
1,310 |
3.7% |
3.7% |
- |
||||||||
Intl |
608 |
601 |
1.2% |
4.8% |
-3.6% |
1,827 |
1,711 |
6.8% |
3.8% |
3.0% |
||||||||
WW |
1,048 |
1,002 |
4.6% |
6.8% |
-2.2% |
3,186 |
3,021 |
5.5% |
3.8% |
1.7% |
||||||||
WOMEN'S HEALTH |
||||||||||||||||||
US |
3 |
3 |
0.0% |
0.0% |
- |
10 |
9 |
11.1% |
11.1% |
- |
||||||||
Intl |
266 |
267 |
-0.4% |
8.0% |
-8.4% |
782 |
779 |
0.4% |
2.0% |
-1.6% |
||||||||
WW |
269 |
270 |
-0.4% |
7.9% |
-8.3% |
792 |
788 |
0.5% |
2.1% |
-1.6% |
||||||||
WOUND CARE / OTHER |
||||||||||||||||||
US |
106 |
104 |
1.9% |
1.9% |
- |
344 |
342 |
0.6% |
0.6% |
- |
||||||||
Intl |
58 |
88 |
-34.1% |
-31.3% |
-2.8% |
183 |
257 |
-28.8% |
-30.0% |
1.2% |
||||||||
WW |
164 |
192 |
-14.6% |
-13.3% |
-1.3% |
527 |
599 |
-12.0% |
-12.5% |
0.5% |
||||||||
TOTAL CONSUMER |
||||||||||||||||||
US |
1,370 |
1,285 |
6.6% |
6.6% |
- |
4,282 |
4,186 |
2.3% |
2.3% |
- |
||||||||
Intl |
2,045 |
2,071 |
-1.3% |
3.7% |
-5.0% |
6,035 |
5,876 |
2.7% |
1.6% |
1.1% |
||||||||
WW |
$ 3,415 |
$ 3,356 |
1.8% |
4.9% |
-3.1% |
$ 10,317 |
$ 10,062 |
2.5% |
1.9% |
0.6% |
||||||||
See footnotes at end of schedule |
||||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||||||||||||
THIRD QUARTER |
NINE MONTHS |
|||||||||||||||||
% Change |
% Change |
|||||||||||||||||
2018 |
2017 |
Reported |
Operational (1) |
Currency |
2018 |
2017 |
Reported |
Operational (1) |
Currency |
|||||||||
PHARMACEUTICAL SEGMENT (2)(5) |
||||||||||||||||||
IMMUNOLOGY |
||||||||||||||||||
US |
$ 2,400 |
$ 2,420 |
-0.8% |
-0.8% |
- |
$ 6,717 |
$ 6,644 |
1.1% |
1.1% |
- |
||||||||
Intl |
998 |
849 |
17.6% |
21.7% |
-4.1% |
3,061 |
2,514 |
21.8% |
18.6% |
3.2% |
||||||||
WW |
3,398 |
3,269 |
3.9% |
5.0% |
-1.1% |
9,778 |
9,158 |
6.8% |
5.9% |
0.9% |
||||||||
REMICADE |
||||||||||||||||||
US |
987 |
1,206 |
-18.2% |
-18.2% |
- |
2,821 |
3,452 |
-18.3% |
-18.3% |
- |
||||||||
US Exports (3) |
100 |
156 |
-35.9% |
-35.9% |
- |
346 |
448 |
-22.8% |
-22.8% |
- |
||||||||
Intl |
292 |
285 |
2.5% |
8.2% |
-5.7% |
921 |
949 |
-3.0% |
-3.9% |
0.9% |
||||||||
WW |
1,379 |
1,647 |
-16.3% |
-15.3% |
-1.0% |
4,088 |
4,849 |
-15.7% |
-15.9% |
0.2% |
||||||||
SIMPONI / SIMPONI ARIA |
||||||||||||||||||
US |
281 |
242 |
16.1% |
16.1% |
- |
779 |
701 |
11.1% |
11.1% |
- |
||||||||
Intl |
255 |
234 |
9.0% |
13.5% |
-4.5% |
823 |
642 |
28.2% |
25.3% |
2.9% |
||||||||
WW |
536 |
476 |
12.6% |
14.8% |
-2.2% |
1,602 |
1,343 |
19.3% |
17.9% |
1.4% |
||||||||
STELARA |
||||||||||||||||||
US |
889 |
800 |
11.1% |
11.1% |
- |
2,460 |
2,027 |
21.4% |
21.4% |
- |
||||||||
Intl |
421 |
324 |
29.9% |
33.0% |
-3.1% |
1,252 |
903 |
38.6% |
32.9% |
5.7% |
||||||||
WW |
1,310 |
1,124 |
16.5% |
17.4% |
-0.9% |
3,712 |
2,930 |
26.7% |
24.9% |
1.8% |
||||||||
OTHER IMMUNOLOGY |
||||||||||||||||||
US |
143 |
16 |
* |
* |
- |
311 |
16 |
* |
* |
- |
||||||||
Intl |
30 |
6 |
* |
* |
* |
65 |
20 |
* |
* |
* |
||||||||
WW |
173 |
22 |
* |
* |
* |
376 |
36 |
* |
* |
* |
||||||||
INFECTIOUS DISEASES |
||||||||||||||||||
US |
345 |
353 |
-2.3% |
-2.3% |
- |
1,006 |
1,020 |
-1.4% |
-1.4% |
- |
||||||||
Intl |
478 |
460 |
3.9% |
7.4% |
-3.5% |
1,496 |
1,334 |
12.1% |
8.1% |
4.0% |
||||||||
WW |
823 |
813 |
1.2% |
3.2% |
-2.0% |
2,502 |
2,354 |
6.3% |
4.0% |
2.3% |
||||||||
EDURANT / rilpivirine |
||||||||||||||||||
US |
13 |
15 |
-13.3% |
-13.3% |
- |
42 |
44 |
-4.5% |
-4.5% |
- |
||||||||
Intl |
189 |
179 |
5.6% |
6.8% |
-1.2% |
581 |
478 |
21.5% |
14.2% |
7.3% |
||||||||
WW |
202 |
194 |
4.1% |
5.2% |
-1.1% |
623 |
522 |
19.3% |
12.6% |
6.7% |
||||||||
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |
||||||||||||||||||
US |
297 |
287 |
3.5% |
3.5% |
- |
847 |
824 |
2.8% |
2.8% |
- |
||||||||
Intl |
193 |
180 |
7.2% |
12.4% |
-5.2% |
613 |
527 |
16.3% |
13.5% |
2.8% |
||||||||
WW |
490 |
467 |
4.9% |
6.9% |
-2.0% |
1,460 |
1,351 |
8.1% |
7.0% |
1.1% |
||||||||
OTHER INFECTIOUS DISEASES |
||||||||||||||||||
US |
35 |
51 |
-31.4% |
-31.4% |
- |
117 |
152 |
-23.0% |
-23.0% |
- |
||||||||
Intl |
96 |
101 |
-5.0% |
-0.3% |
-4.7% |
302 |
329 |
-8.2% |
-9.3% |
1.1% |
||||||||
WW |
131 |
152 |
-13.8% |
-10.7% |
-3.1% |
419 |
481 |
-12.9% |
-13.7% |
0.8% |
||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||||||||||||
THIRD QUARTER |
NINE MONTHS |
|||||||||||||||||
% Change |
% Change |
|||||||||||||||||
2018 |
2017 |
Reported |
Operational (1) |
Currency |
2018 |
2017 |
Reported |
Operational (1) |
Currency |
|||||||||
NEUROSCIENCE |
||||||||||||||||||
US |
651 |
647 |
0.6% |
0.6% |
- |
1,914 |
1,931 |
-0.9% |
-0.9% |
- |
||||||||
Intl |
839 |
851 |
-1.4% |
2.1% |
-3.5% |
2,663 |
2,531 |
5.2% |
2.3% |
2.9% |
||||||||
WW |
1,490 |
1,498 |
-0.5% |
1.5% |
-2.0% |
4,577 |
4,462 |
2.6% |
0.9% |
1.7% |
||||||||
CONCERTA / methlyphenidate |
||||||||||||||||||
US |
57 |
100 |
-43.0% |
-43.0% |
- |
191 |
284 |
-32.7% |
-32.7% |
- |
||||||||
Intl |
100 |
98 |
2.0% |
7.3% |
-5.3% |
322 |
304 |
5.9% |
4.4% |
1.5% |
||||||||
WW |
157 |
198 |
-20.7% |
-18.1% |
-2.6% |
513 |
588 |
-12.8% |
-13.6% |
0.8% |
||||||||
INVEGA SUSTENNA / XEPLION / TRINZA / TREVICTA |
||||||||||||||||||
US |
468 |
395 |
18.5% |
18.5% |
- |
1,306 |
1,154 |
13.2% |
13.2% |
- |
||||||||
Intl |
281 |
248 |
13.3% |
16.6% |
-3.3% |
859 |
722 |
19.0% |
14.2% |
4.8% |
||||||||
WW |
749 |
643 |
16.5% |
17.8% |
-1.3% |
2,165 |
1,876 |
15.4% |
13.5% |
1.9% |
||||||||
RISPERDAL CONSTA |
||||||||||||||||||
US |
76 |
87 |
-12.6% |
-12.6% |
- |
238 |
273 |
-12.8% |
-12.8% |
- |
||||||||
Intl |
99 |
107 |
-7.5% |
-4.0% |
-3.5% |
321 |
335 |
-4.2% |
-7.3% |
3.1% |
||||||||
WW |
175 |
194 |
-9.8% |
-7.9% |
-1.9% |
559 |
608 |
-8.1% |
-9.8% |
1.7% |
||||||||
OTHER NEUROSCIENCE |
||||||||||||||||||
US |
50 |
65 |
-23.1% |
-23.1% |
- |
179 |
220 |
-18.6% |
-18.6% |
- |
||||||||
Intl |
359 |
398 |
-9.8% |
-6.6% |
-3.2% |
1,161 |
1,170 |
-0.8% |
-2.9% |
2.1% |
||||||||
WW |
409 |
463 |
-11.7% |
-9.0% |
-2.7% |
1,340 |
1,390 |
-3.6% |
-5.4% |
1.8% |
||||||||
ONCOLOGY |
||||||||||||||||||
US |
1,250 |
846 |
47.8% |
47.8% |
- |
3,268 |
2,207 |
48.1% |
48.1% |
- |
||||||||
Intl |
1,338 |
1,052 |
27.2% |
31.2% |
-4.0% |
4,087 |
3,012 |
35.7% |
30.9% |
4.8% |
||||||||
WW |
2,588 |
1,898 |
36.4% |
38.6% |
-2.2% |
7,355 |
5,219 |
40.9% |
38.1% |
2.8% |
||||||||
DARZALEX |
||||||||||||||||||
US |
318 |
230 |
38.3% |
38.3% |
- |
880 |
643 |
36.9% |
36.9% |
- |
||||||||
Intl |
180 |
87 |
* |
* |
* |
561 |
228 |
* |
* |
* |
||||||||
WW |
498 |
317 |
57.1% |
60.0% |
-2.9% |
1,441 |
871 |
65.4% |
63.6% |
1.8% |
||||||||
IMBRUVICA |
||||||||||||||||||
US |
334 |
230 |
45.2% |
45.2% |
- |
811 |
622 |
30.4% |
30.4% |
- |
||||||||
Intl |
371 |
282 |
31.6% |
36.6% |
-5.0% |
1,101 |
749 |
47.0% |
42.2% |
4.8% |
||||||||
WW |
705 |
512 |
37.7% |
40.4% |
-2.7% |
1,912 |
1,371 |
39.5% |
36.9% |
2.6% |
||||||||
VELCADE |
||||||||||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||
Intl |
271 |
273 |
-0.7% |
1.8% |
-2.5% |
864 |
843 |
2.5% |
-1.7% |
4.2% |
||||||||
WW |
271 |
273 |
-0.7% |
1.8% |
-2.5% |
864 |
843 |
2.5% |
-1.7% |
4.2% |
||||||||
ZYTIGA |
||||||||||||||||||
US |
527 |
352 |
49.7% |
49.7% |
- |
1,420 |
826 |
71.9% |
71.9% |
- |
||||||||
Intl |
431 |
317 |
36.0% |
38.8% |
-2.8% |
1,292 |
924 |
39.8% |
34.2% |
5.6% |
||||||||
WW |
958 |
669 |
43.2% |
44.5% |
-1.3% |
2,712 |
1,750 |
55.0% |
52.0% |
3.0% |
||||||||
OTHER ONCOLOGY |
||||||||||||||||||
US |
71 |
34 |
* |
* |
- |
157 |
116 |
35.3% |
35.3% |
- |
||||||||
Intl |
85 |
93 |
-8.6% |
-4.7% |
-3.9% |
269 |
268 |
0.4% |
-2.5% |
2.9% |
||||||||
WW |
156 |
127 |
22.8% |
25.6% |
-2.8% |
426 |
384 |
10.9% |
8.9% |
2.0% |
||||||||
PULMONARY HYPERTENSION(4) |
||||||||||||||||||
US |
425 |
371 |
14.6% |
14.6% |
- |
1,215 |
408 |
* |
* |
- |
||||||||
Intl |
231 |
261 |
-11.5% |
-8.9% |
-2.6% |
691 |
309 |
* |
* |
* |
||||||||
WW |
656 |
632 |
3.8% |
4.9% |
-1.1% |
1,906 |
717 |
* |
* |
* |
||||||||
OPSUMIT |
||||||||||||||||||
US |
182 |
150 |
21.3% |
21.3% |
- |
511 |
174 |
* |
* |
- |
||||||||
Intl |
128 |
109 |
17.4% |
20.9% |
-3.5% |
381 |
130 |
* |
* |
* |
||||||||
WW |
310 |
259 |
19.7% |
21.2% |
-1.5% |
892 |
304 |
* |
* |
* |
||||||||
TRACLEER |
||||||||||||||||||
US |
69 |
83 |
-16.9% |
-16.9% |
- |
208 |
85 |
* |
* |
- |
||||||||
Intl |
70 |
127 |
-44.9% |
-43.6% |
-1.3% |
214 |
151 |
41.7% |
37.5% |
4.2% |
||||||||
WW |
139 |
210 |
-33.8% |
-33.0% |
-0.8% |
422 |
236 |
78.8% |
76.1% |
2.7% |
||||||||
UPTRAVI |
||||||||||||||||||
US |
154 |
113 |
36.3% |
36.3% |
- |
433 |
121 |
* |
* |
- |
||||||||
Intl |
17 |
11 |
54.5% |
57.3% |
-2.8% |
49 |
12 |
* |
* |
* |
||||||||
WW |
171 |
124 |
37.9% |
38.1% |
-0.2% |
482 |
133 |
* |
* |
* |
||||||||
OTHER |
||||||||||||||||||
US |
20 |
25 |
-20.0% |
-20.0% |
- |
63 |
28 |
* |
* |
- |
||||||||
Intl |
16 |
14 |
14.3% |
21.2% |
-6.9% |
47 |
16 |
* |
* |
* |
||||||||
WW |
36 |
39 |
-7.7% |
-5.2% |
-2.5% |
110 |
44 |
* |
* |
* |
||||||||
CARDIOVASCULAR / METABOLISM / OTHER |
||||||||||||||||||
US |
1,026 |
1,179 |
-13.0% |
-13.0% |
- |
3,230 |
3,488 |
-7.4% |
-7.4% |
- |
||||||||
Intl |
365 |
406 |
-10.1% |
-6.5% |
-3.6% |
1,196 |
1,177 |
1.6% |
-1.1% |
2.7% |
||||||||
WW |
1,391 |
1,585 |
-12.2% |
-11.3% |
-0.9% |
4,426 |
4,665 |
-5.1% |
-5.8% |
0.7% |
||||||||
XARELTO |
||||||||||||||||||
US |
612 |
635 |
-3.6% |
-3.6% |
- |
1,869 |
1,790 |
4.4% |
4.4% |
- |
||||||||
Intl |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||
WW |
612 |
635 |
-3.6% |
-3.6% |
- |
1,869 |
1,790 |
4.4% |
4.4% |
- |
||||||||
INVOKANA / INVOKAMET |
||||||||||||||||||
US |
150 |
220 |
-31.8% |
-31.8% |
- |
523 |
723 |
-27.7% |
-27.7% |
- |
||||||||
Intl |
40 |
45 |
-11.1% |
-6.7% |
-4.4% |
130 |
121 |
7.4% |
4.8% |
2.6% |
||||||||
WW |
190 |
265 |
-28.3% |
-27.6% |
-0.7% |
653 |
844 |
-22.6% |
-23.0% |
0.4% |
||||||||
PROCRIT / EPREX |
||||||||||||||||||
US |
178 |
168 |
6.0% |
6.0% |
- |
523 |
511 |
2.3% |
2.3% |
- |
||||||||
Intl |
77 |
70 |
10.0% |
12.8% |
-2.8% |
244 |
229 |
6.6% |
2.9% |
3.7% |
||||||||
WW |
255 |
238 |
7.1% |
7.9% |
-0.8% |
767 |
740 |
3.6% |
2.4% |
1.2% |
||||||||
OTHER |
||||||||||||||||||
US |
86 |
156 |
-44.9% |
-44.9% |
- |
315 |
464 |
-32.1% |
-32.1% |
- |
||||||||
Intl |
248 |
291 |
-14.8% |
-11.1% |
-3.7% |
822 |
827 |
-0.6% |
-3.1% |
2.5% |
||||||||
WW |
334 |
447 |
-25.3% |
-22.9% |
-2.4% |
1,137 |
1,291 |
-11.9% |
-13.5% |
1.6% |
||||||||
TOTAL PHARMACEUTICAL |
||||||||||||||||||
US |
6,097 |
5,816 |
4.8% |
4.8% |
- |
17,350 |
15,698 |
10.5% |
10.5% |
- |
||||||||
Intl |
4,249 |
3,879 |
9.5% |
13.2% |
-3.7% |
13,194 |
10,877 |
21.3% |
17.5% |
3.8% |
||||||||
WW |
$ 10,346 |
$ 9,695 |
6.7% |
8.2% |
-1.5% |
$ 30,544 |
$ 26,575 |
14.9% |
13.4% |
1.5% |
||||||||
See footnotes at end of schedule |
||||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
||||||||||||||||||
THIRD QUARTER |
NINE MONTHS |
|||||||||||||||||
% Change |
% Change |
|||||||||||||||||
2018 |
2017 |
Reported |
Operational (1) |
Currency |
2018 |
2017 |
Reported |
Operational (1) |
Currency |
|||||||||
MEDICAL DEVICES SEGMENT (2)(5) |
||||||||||||||||||
DIABETES CARE |
||||||||||||||||||
US |
$ 125 |
$ 168 |
-25.6% |
-25.6% |
- |
$ 371 |
$ 482 |
-23.0% |
-23.0% |
- |
||||||||
Intl |
190 |
237 |
-19.8% |
-16.0% |
-3.8% |
638 |
743 |
-14.1% |
-16.3% |
2.2% |
||||||||
WW |
315 |
405 |
-22.2% |
-20.0% |
-2.2% |
1,009 |
1,225 |
-17.6% |
-19.0% |
1.4% |
||||||||
DIAGNOSTICS |
||||||||||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||
Intl |
- |
- |
- |
- |
- |
- |
1 |
* |
* |
* |
||||||||
WW |
- |
- |
- |
- |
- |
- |
1 |
* |
* |
* |
||||||||
INTERVENTIONAL SOLUTIONS |
||||||||||||||||||
US |
320 |
279 |
14.7% |
14.7% |
0.0% |
947 |
843 |
12.3% |
12.3% |
- |
||||||||
Intl |
333 |
274 |
21.5% |
24.1% |
-2.6% |
1,013 |
832 |
21.8% |
17.5% |
4.3% |
||||||||
WW |
653 |
553 |
18.1% |
19.4% |
-1.3% |
1,960 |
1,675 |
17.0% |
14.9% |
2.1% |
||||||||
ORTHOPAEDICS |
||||||||||||||||||
US |
1,284 |
1,308 |
-1.8% |
-1.8% |
- |
3,923 |
4,034 |
-2.8% |
-2.8% |
- |
||||||||
Intl |
827 |
896 |
-7.7% |
-4.4% |
-3.3% |
2,700 |
2,738 |
-1.4% |
-4.6% |
3.2% |
||||||||
WW |
2,111 |
2,204 |
-4.2% |
-2.9% |
-1.3% |
6,623 |
6,772 |
-2.2% |
-3.5% |
1.3% |
||||||||
HIPS |
||||||||||||||||||
US |
201 |
195 |
3.1% |
3.1% |
- |
621 |
612 |
1.5% |
1.5% |
- |
||||||||
Intl |
129 |
133 |
-3.0% |
1.0% |
-4.0% |
432 |
418 |
3.3% |
0.1% |
3.2% |
||||||||
WW |
330 |
328 |
0.6% |
2.2% |
-1.6% |
1,053 |
1,030 |
2.2% |
0.9% |
1.3% |
||||||||
KNEES |
||||||||||||||||||
US |
215 |
220 |
-2.3% |
-2.3% |
- |
672 |
702 |
-4.3% |
-4.3% |
- |
||||||||
Intl |
126 |
123 |
2.4% |
6.8% |
-4.4% |
438 |
424 |
3.3% |
0.2% |
3.1% |
||||||||
WW |
341 |
343 |
-0.6% |
1.0% |
-1.6% |
1,110 |
1,126 |
-1.4% |
-2.6% |
1.2% |
||||||||
TRAUMA |
||||||||||||||||||
US |
395 |
398 |
-0.8% |
-0.8% |
- |
1,196 |
1,179 |
1.4% |
1.4% |
- |
||||||||
Intl |
259 |
264 |
-1.9% |
1.0% |
-2.9% |
829 |
768 |
7.9% |
4.4% |
3.5% |
||||||||
WW |
654 |
662 |
-1.2% |
0.0% |
-1.2% |
2,025 |
1,947 |
4.0% |
2.6% |
1.4% |
||||||||
SPINE & OTHER |
||||||||||||||||||
US |
473 |
495 |
-4.4% |
-4.4% |
- |
1,434 |
1,541 |
-6.9% |
-6.9% |
- |
||||||||
Intl |
313 |
376 |
-16.8% |
-13.9% |
-2.9% |
1,001 |
1,128 |
-11.3% |
-14.3% |
3.0% |
||||||||
WW |
786 |
871 |
-9.8% |
-8.6% |
-1.2% |
2,435 |
2,669 |
-8.8% |
-10.1% |
1.3% |
||||||||
SURGERY |
||||||||||||||||||
US |
1,016 |
1,002 |
1.4% |
1.4% |
- |
3,031 |
3,009 |
0.7% |
0.7% |
- |
||||||||
Intl |
1,360 |
1,344 |
1.2% |
5.6% |
-4.4% |
4,283 |
3,992 |
7.3% |
5.0% |
2.3% |
||||||||
WW |
2,376 |
2,346 |
1.3% |
3.8% |
-2.5% |
7,314 |
7,001 |
4.5% |
3.2% |
1.3% |
||||||||
ADVANCED |
||||||||||||||||||
US |
421 |
398 |
5.8% |
5.8% |
- |
1,216 |
1,190 |
2.2% |
2.2% |
- |
||||||||
Intl |
555 |
525 |
5.7% |
10.0% |
-4.3% |
1,731 |
1,543 |
12.2% |
9.5% |
2.7% |
||||||||
WW |
976 |
923 |
5.7% |
8.1% |
-2.4% |
2,947 |
2,733 |
7.8% |
6.3% |
1.5% |
||||||||
GENERAL |
||||||||||||||||||
US |
423 |
430 |
-1.6% |
-1.6% |
- |
1,282 |
1,276 |
0.5% |
0.5% |
- |
||||||||
Intl |
657 |
675 |
-2.7% |
1.6% |
-4.3% |
2,094 |
2,017 |
3.8% |
1.5% |
2.3% |
||||||||
WW |
1,080 |
1,105 |
-2.3% |
0.3% |
-2.6% |
3,376 |
3,293 |
2.5% |
1.1% |
1.4% |
||||||||
SPECIALTY |
||||||||||||||||||
US |
172 |
174 |
-1.1% |
-1.1% |
- |
533 |
543 |
-1.8% |
-1.8% |
- |
||||||||
Intl |
148 |
144 |
2.8% |
7.9% |
-5.1% |
458 |
432 |
6.0% |
4.9% |
1.1% |
||||||||
WW |
320 |
318 |
0.6% |
2.9% |
-2.3% |
991 |
975 |
1.6% |
1.1% |
0.5% |
||||||||
VISION |
||||||||||||||||||
US |
452 |
432 |
4.6% |
4.6% |
- |
1,351 |
1,142 |
18.3% |
18.3% |
- |
||||||||
Intl |
680 |
659 |
3.2% |
6.2% |
-3.0% |
2,069 |
1,802 |
14.8% |
12.6% |
2.2% |
||||||||
WW |
1,132 |
1,091 |
3.8% |
5.6% |
-1.8% |
3,420 |
2,944 |
16.2% |
14.9% |
1.3% |
||||||||
CONTACT LENSES / OTHER |
||||||||||||||||||
US |
319 |
302 |
5.6% |
5.6% |
- |
948 |
832 |
13.9% |
13.9% |
- |
||||||||
Intl |
516 |
498 |
3.6% |
6.4% |
-2.8% |
1,538 |
1,404 |
9.5% |
7.4% |
2.1% |
||||||||
WW |
835 |
800 |
4.4% |
6.2% |
-1.8% |
2,486 |
2,236 |
11.2% |
9.9% |
1.3% |
||||||||
SURGICAL |
||||||||||||||||||
US |
133 |
130 |
2.3% |
2.3% |
- |
403 |
310 |
30.0% |
30.0% |
- |
||||||||
Intl |
164 |
161 |
1.9% |
5.5% |
-3.6% |
531 |
398 |
33.4% |
31.0% |
2.4% |
||||||||
WW |
297 |
291 |
2.1% |
4.1% |
-2.0% |
934 |
708 |
31.9% |
30.5% |
1.4% |
||||||||
TOTAL MEDICAL DEVICES |
||||||||||||||||||
US |
3,197 |
3,189 |
0.3% |
0.3% |
- |
9,623 |
9,510 |
1.2% |
1.2% |
- |
||||||||
Intl |
3,390 |
3,410 |
-0.6% |
3.0% |
-3.6% |
10,703 |
10,108 |
5.9% |
3.2% |
2.7% |
||||||||
WW |
$ 6,587 |
6,599 |
-0.2% |
1.7% |
-1.9% |
$ 20,326 |
$ 19,618 |
3.6% |
2.2% |
1.4% |
||||||||
* Percentage greater than 100% or not meaningful |
||||||||||||||||||
(1) Operational growth excludes the effect of translational currency |
||||||||||||||||||
(2) Unaudited |
||||||||||||||||||
(3) Reported as |
||||||||||||||||||
(4) Products acquired from |
||||||||||||||||||
(5) Prior year amounts have been reclassified to conform to current year product disclosure |
View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2018-third-quarter-results-300731779.html
SOURCE
News Provided by Acquire Media